Tech Center 1600 • Art Units: 1622 1626 1639 1675 1692
This examiner grants 53% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17749462 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Final Rejection | Samsung Electronics Co., Ltd. |
| 18236462 | METHODS FOR TREATING RECEPTOR-INTERACTING PROTEIN KINASE 1-MEDIATED DISEASES | Non-Final OA | Genzyme Corporation |
| 18082799 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 14407174 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | Final Rejection | Takeda Pharmaceutical Company Limited |
| 17918084 | METHODS AND COMPOSITION FOR TREATMENT OF COVID-19 ILLNESS REQUIRING HOSPITALIZATION | Non-Final OA | OHIO STATE INNOVATION FOUNDATION |
| 17916843 | Synthesis of vinylic alcohol intermediates | Non-Final OA | AMGEN INC. |
| 18261182 | PROCESS FOR PRODUCTION OF INTERMEDIATES | Final Rejection | DSM IP Assets B.V. |
| 18318947 | 2-PHENYLBENZOTRIAZOL-5-AMINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS (HBV) INFECTION | Non-Final OA | Hoffmann-La Roche Inc. |
| 18258711 | CRYSTALLINE FORM I OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME | Non-Final OA | LG CHEM, LTD. |
| 18258717 | CRYSTALLINE FORM II OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR | Non-Final OA | LG CHEM, LTD. |
| 19216139 | METHODS AND KITS FOR LABELING CELLULAR MOLECULES | Final Rejection | University of Washington |
| 18455152 | METHODS AND KITS FOR LABELING CELLULAR MOLECULES | Non-Final OA | University of Washington |
| 19190210 | METHODS FOR THE TREATMENT OF BIOLOGICAL AGING | Final Rejection | BIOVIE INC. |
| 18001832 | TREATMENT OF VIRAL INFECTIONS WITH ESTROGEN RECEPTOR MODULATORS AND ANTI-INFLAMMATORY AGENTS | Final Rejection | THE CLEVELAND CLINIC FOUNDATION |
| 18058216 | METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODING | Non-Final OA | Becton, Dickinson and Company |
| 18286510 | Combination Comprising Ribociclib and Amcenestrant | Non-Final OA | Sanofi |
| 17927642 | Gasdermin D (GSDMD) Succination for the Treatment of Inflammatory Disease | Final Rejection | University of Massachusetts |
| 17999581 | METHODS FOR TREATING DEPRESSION | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18556969 | METHODS FOR TREATING SYMPTOMS OF KABUKI SYNDROME | Non-Final OA | UNIVERSITY OF SOUTH FLORIDA |
| 17934517 | Methods for Identifying Multiple Epitopes in Selected Sub-Populations of Cells | Final Rejection | Roche Sequencing Solutions, Inc. |
| 18147251 | REFINING METHOD | Final Rejection | NGK Insulators, Ltd. |
| 18173386 | NUCLEIC ACID EXTRACTION AND AMPLIFICATION CONTROLS AND METHODS OF USE THEREOF | Final Rejection | LIFE TECHNOLOGIES CORPORATION |
| 18066103 | METHOD FOR DETERMINING A DRUG COMBINATION VIA A BLOCKING MODEL OF A MULTI-SITE-TARGETED PROTEIN AND APPLICATIONS THEREOF | Final Rejection | National Tsing Hua University |
| 17787952 | WATER-SOLUBLE CONJUGATED POLYMER FOR PHOTOTHERMAL THERAPY, POLYMERIZED MONOMER THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Final Rejection | SOUTH CHINA UNIVERSITY OF TECHNOLOGY |
| 18001333 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | Non-Final OA | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY |
| 17996302 | INHIBITION OF BAX-MEDIATED CELL DEATH BY ELTROMBOPAG | Final Rejection | Albert Einstein College of Medicine |
| 18530255 | SOLID FORMS OF A SGC ACTIVATOR | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18735600 | OCULAR FORMULATIONS FOR DRUG-DELIVERY TO THE POSTERIOR SEGMENT OF THE EYE | Non-Final OA | PanOptica, Inc. |
| 17890782 | DIAGNOSTIC METHODS FOR INFLAMMATORY DISORDERS | Final Rejection | Meso Scale Technologies, LLC. |
| 18340824 | METHODS AND POLYNUCLEOTIDES FOR AMPLIFYING A TARGET POLYNUCLEOTIDE | Non-Final OA | Oxford Nanopore Technologies PLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy